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Background: Data on self perception of drug allergy in the general population are lacking. Epidemio-
logical studies focus either on speciﬁc populations or document adverse drug reactions in general. Our
objective was to document self-reported drug allergy in Greece, through a simple, informative internet-
based questionnaire.
Methods: A questionnaire on drug allergy was accessible online for a 3-month period. Participants
voluntarily answered 28 questions referring to: suspected drug, clinical manifestations, concomitant
factors, received treatment, reaction's re-occurrence.
Results: A total of 2528 questionnaires were included in study analysis. Beta-lactams and non-steroidal
anti-inﬂammatory drugs were the most prevalent culprit agents (53% and 27.5% respectively) while half
of the participants acknowledged skin manifestations as the most common symptoms. One out of three
reported subsequent exposure to the drug presumed to be responsible for the reaction and 74.5% of those
stated a new reaction upon re-exposure. Only 26.7% underwent allergological evaluation. Reactions
manifested with respiratory or cardiovascular symptoms, parenteral administration of the culprit drug
and personal history of allergy to agents of >1 different pharmacological categories were associated with
increased risk of hospitalization.
Conclusions: Allergic reactions to drugs are adverse events difﬁcult to deﬁne and diagnose. A remarkable
proportion of presumed as hypersensitivity reactions are not referred to allergists; therefore these pa-
tients may be either re-exposed to potentially noxious drugs, or needlessly avoid whole classes of drugs
as b-lactams for more costly or less appropriate treatments. Internet-based questionnaires may
contribute to awareness programs concerning drug allergy and help improve proper referral.
Copyright © 2016, Japanese Society of Allergology. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Adverse drug reactions (ADRs) account for 3e6% of hospital
admissions while their prevalence among hospitalized patients is
estimated between 10 and 15%. ADRs represent a major health
problem with increased morbidity, prolonged hospitalization and
risk of mortality. According to the World Health Organization, an
ADR is deﬁned as “a response to a medicine which is noxious andmitros”, “Attikon” University
ece.
Makris).
ety of Allergology.
rgology. Production and hosting by Elseunintended, and which occurs at doses normally used in man”.1
Furthermore ADRs are divided in Type A that are predictable and
dose-dependent and Type B that are unpredictable, dose inde-
pendent and comprise 15e20% of all ADRs. The latter group in-
cludes both immunologically mediated drug hypersensitivity
(alternatively called drug allergy) and non-immune mediated
reactions.1
Although drug allergy is of major importance, its true incidence
and other epidemiological features are not well studied. The vast
majority of epidemiologic data refers rather to ADRs than to drug
allergy speciﬁcally.2 Besides, a great confusion about drug allergy
exists among health care providers and patients. Previous studies
reported a large number of medication errors and hospital admis-
sions due to allergic reactions attributed to drugs in outpatientvier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
Table 1
Descriptive characteristics of study participants.
Variables N (%)
Male sex 762 (30.3)
Education
Primary (6 years) 67 (2.7)
Secondary (9 years) 67 (2.7)
High school (12 years) 844 (33.9)
University 1512 (60.7)
Age at ﬁrst reaction (years)
0e10 299 (11.9)
11e20 446 (17.8)
21e30 818 (32.6)
31e40 444 (17.7)
41e50 220 (8.8)
51e60 124 (4.9)
>60 157 (6.3)
Administration of the culprit drug
by injection (IM or IV)
312 (12.4)
Occurrence of the reaction at home 2225 (89.4)
Time interval between drug intake
and symptoms' onset
1e3 h 1292 (51.7)
3e72 h 799 (32.0)
>72 h after the initiation of treatment 361 (14.4)
After the completion of treatment 49 (2.0)
Hospitalization 989 (39.4)
Duration of symptoms
<4 h 1095 (43.7)
1e7 days 1119 (44.6)
>7 days 293 (11.7)
Repeated intake of the culprit drug 737 (29.3)
Co-existing factors 1254 (49.6)
History of allergy to agents of >1 different
pharmacological categories
782 (31.5)
Personal history of atopy (allergic rhinitis,
asthma, atopic dermatitis)
1303 (51.5)
Family history of atopy (ﬁrst-degree relative) 1123 (48.0)
Previous surgery 1242 (49.5)
Chronic concomitant diseases 342 (13.9)
Allergological evaluation with skin testing 666 (26.7)
Treating physician
No evaluation at all 854 (34.3)
Allergist 574 (23.0)
Other than allergist 1065 (42.7)
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are referred to specialists and therefore only in these cases the
diagnosis is well documented; thus studies that use clinical ques-
tionnaires for addressing drug allergy may not present the “real
life” situation.
Internet portals have created new opportunities for the assess-
ment of numerous medical conditions. Internet-based question-
naires encourage a greater number of individuals from a broad
geographic area to take part providing thus the opportunity to
perform wide scale surveys by overcoming traditional problems
like high ﬁnancial costs. Information transmitted via secure portals
could allow for the identiﬁcation of chronic problems even better
than visits to non-specialists in thesemedical entities. Based on this
information, the web-users can provide important data about
certain medical conditions that reﬂect the patients' perception
about their own problem. However, a selection bias to internet-
users exclusively and self-reporting are potential limitations. Our
previous experience with internet surveys was very positive as we
revealed interesting aspects about the patients' perspective and the
way they handle disease.4,5
We have conducted this study in order to record self perception
of drug allergy among internet users in Greece. Secondary goals of
the study were the assessment of management of these conditions,
the compliance of patients to the advice provided by treating
physicians, as well as the identiﬁcation of risk factors for severe
reactions.
Methods
Study design
A speciﬁc questionnaire (Supplementary Table 1) on drug al-
lergy was generated by Drug Allergy Outpatient Clinic, Allergy Unit,
Attikon General University Hospital, Athens, Greece. Subsequently,
the questionnaire, consisted of 28 questions, was placed on the
website of http://www.in.gr, one of the most reliable online infor-
mation portals in Greece which includes a popular “health zone”
through distinguished links placed on this site. All online visitors
with personal history of drug allergy were invited to take part in
the study through an introductory page. The questionnaire was
posted by Internet portal for a 3-month period. Each participant
could ﬁll the questionnaire only once; to this end, a safety feature of
the website prohibited voting from the same IP address more than
once. Individuals without a history of drug allergy were excluded
from the study by an introductory screening question (No 6,
Supplementary Table 1). Demographic data including age, gender
and address zip code of participants were also collected. Partici-
pants younger than 12 years were excluded from data analysis.
Study subjects participated anonymously and the introductory
page clearly stated that the obtained data would be used for
epidemiological research only. After study analysis, the most
important results and conclusions as well as general information
and recommendations for drug allergy sufferers, were posted at the
same portal.
The protocol was approved by the Ethics Committee of Attikon
University Hospital.
Statistical analysis
Statistical analysis consisted of two steps. First, descriptive sta-
tistics were calculated. Continuous variables are presented as mean
values ± standard deviation (SD), whereas categorical variables are
presented as absolute and relative frequencies. Secondly, potential
risk factors were evaluated along three main axes: (i) hospitaliza-
tion; (ii) repeated intake of the allergenic drug after the ﬁrstreaction; and (iii) reported subsequent speciﬁc allergological
evaluation with skin testing. Multivariate logistic regression was
performed; the factors that were signiﬁcantly associated with the
aforementioned items at the univariate analysis were examined as
independent variables.
In the ﬁnal model, after mutual adjustment, only the statistically
signiﬁcant variables were included (backward selection statistical
procedure). Similarly to our previous work,5 a hierarchical
approach was adopted concerning the modeling of the three axes.
The underlying conceptual framework envisaged the time succes-
sion: ﬁrst (serious) reaction/ hospitalization/ non-compliance
with medical advice (repeated intake of the allergenic drug after
the reaction) or compliance with medical advice (and allergological
evaluationwith skin testing). Consequently, the model for repeated
intake also encompassed hospitalization as an independent vari-
able, whereas the model concerning skin testing examined both
hospitalization and subsequent intake of the culprit drug.
Symptoms were grouped according to the affected organ and
system: upper (nasal congestion, runny nose, sneezing, ocular itch
and or hemosis of conjunctiva) and lower respiratory system (chest
tightness, wheezing, dry cough, voice hoarseness), skin (urticaria
eangioedema, maculopapular exanthema, itching, generalized
ﬂushing), cardiovascular (tachycardia, dizziness, loss of conscious-
ness), gastrointestinal (abdominal pain, diarrhea, vomiting) and
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able i.e. any (stress, exercise, infection, fever) vs. none. Regarding
the follow-up of patients, the distinction was made between
consultation by an allergist or specialist on other specialties
(dermatology, internal medicine or general practice) and non-
medical consultation at all. The level of statistical signiﬁcance was
set at 0.05. All analyses were performed with STATA version 11.1
(STATA Corporation, College Station, TX, USA).
Results
Epidemiological data
The ﬁnal dataset that was included in study analysis consisted of
2528 responders of a mean age 35.6 ± 11.1 years (range 12e77
years). The descriptive characteristics of the participants are pre-
sented on Table 1. The culprit drugs for the reaction according to
patients' reports were: antibiotics (1297 patients, 53.0%), non-
steroidal anti-inﬂammatory drugs (NSAIDs; 674pts, 27.5%), local
corticosteroids (66pts, 2.7%), general anesthetics (62pts, 2.5%),
vaccines (32pts, 1.3%), radio contrast media and ﬂuorescein (25pts,
1.0%), local anesthetics (30pts, 1.2%), chemotherapeutic agents
(6pts, 0.25%); the remaining 10.5% consisted of various other
agents.
Coexisting factors were reported by 1254 patients; the most
prevalent were fever (n ¼ 415, 33.1%), infection (n ¼ 415, 33.1%),
emotional stress (n ¼ 396, 31.6%) and physical exercise (n ¼ 28,
2.2%).
Clinical characteristics
The clinical manifestations according to the systems' involve-
ment are depicted on Fig. 1. The most common symptoms from
different systems were: a/among 1233 subjects with skin mani-
festations: ﬂushing 31.1%, urticaria ± angioedema 27.6%, mac-
ulopapular rash 22.9%, pustular or bullous rash 5.7%, sole
angioedema 5.2%, generalized pruritus 3%, eczema 2.4% and exfo-
liate dermatitis or necrotic dermatoses 2%, b/among 413 subjects
with cardiovascular symptoms: loss of consciousness 37.3%, dizzi-
ness 32.9% and tachycardia 29.8%, c/among 262 subjects with lower
airways' manifestations: chest tightness 77.5%, voice hoarseness
20.2% and wheezing-dry cough 6.9%, d/among 183 subjects with
gastrointestinal symptoms: nausea-vomiting 38.8%, abdominal0 200 400 600 800 1000 1200 1400
Other
Upper respiratory
Gastrointestinal
Lower respiratory
Cardiovascular
Skin
No of participants
Affected system
Fig. 1. Systems' involvement in the reported allergic reactions.pain 31.1% and diarrhea 30.1%, e/among 159 subjects with upper
respiratory symptoms: orbital edema 47.2%, ocular itch and/or
hemosis of conjunctiva 23.9%, nasal congestion 9.4%, runny nose
3.8%. Other variable symptoms (arthralgia/myalgia, jaundice, mal-
aise, lymphadenopathy, neuropathy, renal dysfunction) were re-
ported by 9.4% of participants.
A high percentage of participants (737/2528, 29.3%) reported
subsequent intake of the culprit drug; among them, 556 (75.4%)
reported reoccurrence of allergic reaction after re-administration of
the offending drug. According to reactors' perception, the reaction
was less severe in 91/556 of cases (16.4%), equally severe with the
prior one in 373/556 of cases (67.1%) and more severe in 92/556
(16.6%) respectively.
Multivariate analysis
The results of the multivariate logistic regression for hospitali-
zations are presented on Table 2. Accordingly, presence of lower
respiratory symptoms (OR ¼ 2.47) or cardiovascular symptoms
(OR ¼ 2.16), administration of the culprit drug via intravenous or
intramuscular injection (OR ¼ 1.60), history of allergic reactions to
>1 agents of different pharmacological categories (OR ¼ 1.21) were
associated with increased risk for hospitalization; on the contrary,
delayed onset of symptoms after drug intake (OR ¼ 0.87), higher
educational level (OR ¼ 0.86) and occurrence of the reaction at
home (OR ¼ 0.56) were identiﬁed as protective from
hospitalization.
Referring subsequent intake of the culprit drug the multivariate
analysis has shown that presence of any concomitant chronic dis-
ease (OR ¼ 1.61), male sex (OR ¼ 1.42), reaction to Non-Steroids
Anti-inﬂammatory Drugs (OR ¼ 1.40), prior history of surgical
procedures (OR ¼ 1.38) and multiple reactions to different drugs
(OR ¼ 1.36) were predisposing factors for re-consumption of the
culprit agent. On the other hand, history of hospitalization after
previous drug allergic reaction (OR ¼ 0.75), antibiotic allergy
(OR ¼ 0.75), as well as parenteral administration (OR ¼ 0.65)
seemed to protect from any subsequent intake of the culprit drug
(Table 3).
The analysis for speciﬁc allergological evaluation with in vivo
testing after the reaction is presented in Table 4. In case of vaccine
suspected allergy testing was performed more frequently
(OR ¼ 2.54), as well as in case of personal history of atopyTable 2
Multivariate logistic regression analysis for hospitalization.
Variables retained Category or increment OR (95% CI) p-value
Lower airways
symptoms
Lower respiratory vs.
non-cardiovascular/
non-lower respiratory
symptoms
2.47 (1.87e3.25) <0.001
Cardiovascular
symptoms
Cardiovascular vs.
non-cardiovascular/
non-lower
respiratory symptoms
2.16 (1.71e2.73) <0.001
Injected administration
of the drug
Injection (IV, IM, SC) vs.
all other ways of
administration
1.60 (1.16e2.21) 0.004
History of allergic
reactions to
agents of >1 different
pharmacological
categories
More than one vs.
one category
1.21 (1.00e1.45) 0.045
Delayed symptoms' onset One level increase 0.87 (0.77e0.97) 0.014
Higher education One level increase 0.86 (0.76e0.98) 0.021
Occurrence at home Occurrence at home vs.
elsewhere
0.56 (0.40e0.79) 0.001
OR, odds ratio; 95% CI, conﬁdence interval.
Table 4
Multivariate logistic regression analysis for allergological evaluation.
Variables retained Category or increment OR (95% CI) p-value
Vaccine as the Vaccines vs. all others 2.54 (1.00e6.46) 0.050
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specialties than allergy (OR ¼ 0.07) or no referral to any physician
after the reaction (OR ¼ 0.02) strongly predicted lack of allergo-
logical testing.allergenic agent
Personal history of
another allergy
Yes vs. No 1.76 (1.39e2.24) <0.001
Treating physician
of specialty other
than allergology
Treating physician of a
specialty other than
allergist vs. treated
by an allergist
0.07 (0.05e0.09) <0.001
No physician's
consultation
No treating physician vs.
treated by an allergist
0.02 (0.01e0.03) <0.001
OR, odds ratio; 95% CI, conﬁdence interval.Discussion
To our knowledge, this study represents the largest internet-
based attempt to document self-reported drug allergy, ever con-
ducted. Although this kind of studies bear major limitations that
will be discussed below in detail, we think that our study provides
important information on risk factors for severe reactions and on
the self-perception of drug allergy and subsequent behavior of the
sufferers in relation to future consumption of the culprit drugs. The
actual prevalence in the general population may be more appro-
priately addressed through spontaneous reporting to Pharmacovi-
gilance Programs although several factors as the complexity of drug
allergies, the patients' perception, the somewhat obscure distinc-
tion between true allergic and other hypersensitivity reactions
critically inﬂuence the reported prevalence.6e7 Data from the Ital-
ian Interrogational Group of Pharmacovigilance were reviewed
speciﬁcally for orally administered drugswith 11.6% of the reactions
been attributed to drug hypersensitivity while antibiotics and
NSAIDS were more commonly implicated.8 To date, the only pub-
lished survey on self-reported drug allergy was conducted among
2309 Portuguese adults and prevalence was estimated to be 7.8%.9
Investigation of possible risk factors for drug allergy was a
principal concern of this study, as previous epidemiological studies
were conducted on speciﬁc populations or gave inconclusive re-
sults.10,11 Risk factors including drug and host related factors;
ethnicity and genetics appear to be increasingly important in the
predisposition to certain types of drug allergy.12 From the clinical
perspective, female predominance (almost 60%) is in concordance
to all previous studies.9,13 Other risk factors as atopic status, pre-
vious reactions to different pharmacological agents, and chronic
illnesses were present in a signiﬁcant percentage of individuals
(31.5, 51.5 and 13.9% respectively). Concerning the relevance of age
to the development of drug allergy, a matter not yet fully eluci-
dated14 our ﬁndings are probably biased by the fact that certain age
groups are underrepresented on internet surveys. Speciﬁc ques-
tions concerning concomitant factors that may promote or aggra-
vate reactions were addressed; fever and infection were most
common, probably accounting for the antibiotic and/or NSAIDTable 3
Multivariate logistic regression analysis for repeated intake of the culprit drug.
Variables retained Category or increment OR (95% CI) p-value
Chronic concomitant
disease
Yes vs. no 1.61 (1.25e2.07) <0.001
Male sex Male vs. female 1.42 (1.17e1.73) 0.001
Allergy to Non-steroid
anti-inﬂammatory
drugs
Non-steroid
anti-inﬂammatory
drugs vs. all others
1.40 (1.06e1.85) 0.018
Prior surgery Yes vs. no 1.38 (1.15e1.67) 0.001
Reactions to drugs of
more than one
different classes
More than one vs.
one drug class
1.36 (1.11e1.65) 0.003
Hospitalization due
to drug allergy
Yes vs no 0.75 (0.61e0.90) 0.003
Antibiotics as
offending drug
Antibiotics vs. all other
medications
0.75 (0.58e0.97) 0.028
Injected administration
of the drug at the
ﬁrst episode
Injection (IV, IM, SC) vs.
all other ways of
administration
0.65 (0.47e0.90) 0.010
OR, odds ratio; 95% CI, conﬁdence interval.consumption that caused the reaction. Emotional stress was also
commonly reported among the reactors.
In all epidemiological studies, skin was the organ most
commonly affected by drug hypersensitivity reactions. Among
hospitalized patients, skin involvement was observed in the
70e98% of cases, regardless of the type of the hypersensitivity re-
action (immediate or delayed).15,16 In our population, cutaneous
symptoms were also the leading complain, reported by almost half
of the participants.
Data on re-exposure are particularly interesting; surprisingly
one out of three patients was re-exposed to the offending drug and
the majority (75.4%) reacted again in a similar pattern. A recent
study evaluating physician knowledge and practice patterns
regarding drug allergy in a university medical center revealed that
only 30.64% of patients would react if given the suspended drug
again but only 15.05% stated that they would give the drug in this
situation.17 According to our ﬁndings patients suffering from a
chronic disease, those with a history of previous surgeries or those
reporting reactions to multiple drug classes were more frequently
re-exposed. A probable explanation is that in allergic reactions
during multiple drug intakes, the culprit drug may probably elude
and not be abolished. Re-exposure without proper testing and
consultation by an allergist should be avoided as potentially
harmful.18 A recent study investigating the perception of drug al-
lergy among 800 family doctors from Bucharest, via questionnaire
with 21 speciﬁc questions either directly or via internet, revealed
an underestimation of the severity of drug allergy, a surprisingly
high percentage of allergy skin tests or blood tests recommended
by general practitioners without specialist advice, and persistent
conﬁdence in alternative medicine.19
Hospitalization is a relatively accurate indicator of more severe
adverse reactions to drugs. The multivariate analysis of our survey
revealed an increased risk for hospitalization in cases with alarm-
ing symptoms (i.e. from the cardiovascular or the lower respiratory
systems), prior history of multiple drug allergies and intravenous
administration of drugs.
Standard limitations exist in an internet based study and must
be considered carefully at the interpretation of the results. The
major weakness of the study is the questionnaire-based self-
reporting of reactions occasionally reﬂecting what the participants
perceive to be allergic in nature. Objective evaluation of the quality
or the severity of symptoms present during these reactions as well
as proper diagnostic procedures, even when applied, were not
recorded in this survey. Additionally, participants cannot be
randomly selected. On the other hand, the number of participants
enrolled is considerably high and moreover increasing the strength
of the statistical analysis. In conclusion our study presents the real
life situation of drug allergy according to patients' perception. The
often misguided perception may hamper compliance or future ef-
forts for optimal therapy. Even worse, re-exposure to a drug
allergen may cause a devastating allergic reaction. Among others,
M.P. Makris et al. / Allergology International 66 (2017) 59e63 63our study dictates the need for better acknowledgement and
referring of hypersensitivity reactions to drugs.
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Supplementary data related to this article can be found at http://
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